Anika Therapeutics, Inc. 4
4 · Anika Therapeutics, Inc. · Filed Feb 28, 2017
Insider Transaction Report
Form 4
Ahn Edward S.
Chief Tech. & Strategy Officer
Transactions
- Sale
Common Stock
2017-02-24$49.47/sh−640$31,661→ 7,260 total - Award
Stock Option (Right to Buy)
2017-02-24+11,500→ 11,500 totalExercise: $38.11Exp: 2026-02-04→ Common Stock (11,500 underlying)
Footnotes (3)
- [F1]The exercise price of the stock options represents the closing price of the Company's common stock on the grant date, February 4, 2016, the date the Compensation Committee of the Company granted these performance-based stock option awards (the "Performance Grant"). Please also see notes 2 and 3.
- [F2]On February 24, 2017, the Compensation Committee determined and certified that 125% of the initial Performance Grant had been earned, subject to time-based vesting. Please also see notes 1 and 3.
- [F3]The stock options vest in four equal installments on the following dates: February 24, 2017, January 1, 2018, January 1, 2019 and January 1, 2020.